Bayer (ETR:BAYN) has been upgraded to Buy in a report by Citigroup Corp. today.
- Updated: September 15, 2016
Citigroup Corp. has upgraded Bayer(ETR:BAYN) to Buy in a statement released on 9/16/2016.
Previously on 8/29/2016, Citigroup Corp. reported on Bayer(ETR:BAYN) upped the target price from 0.00EUR to 120.00EUR. At the time, this indicated a possible upside of 0.24%.
Just yesterday Bayer (ETR:BAYN) traded 0.00% even at 91.44EUR. The company’s 50-day average is 0.04EUR and its two hundred day moving average is 0.03EUR. With the last stock close up 1.82% relative to the two hundred day moving average, compared to the S&P 500 which has fallen -0.01% over the same time period. 0 shares of the stock traded hands, down from ann avg. trading volume of 211.
See Graphic Below:
With a market cap of 0.0 EUR, Bayer has a one-year low of 0.03EUR and a 52 week high of 0.04EUR with a price-earnings ratio of 0.
Brief Synopsis On Bayer (ETR:BAYN)
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, and adhesives and sealants; and selected chemical intermediates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.